Guggenheim Initiates Coverage of Entera Bio with Buy
Fintel reports that on September 25, 2026, Guggenheim initiated coverage of Entera Bio (NASDAQCM:ENTX) (DB:5DT) with a Buy recommendation.
This initiation follows other recent analyst actions. On September 22, 2026, Cantor Fitzgerald initiated coverage of the company with an Overweight rating. Prior to that, on September 18, 2026, Leerink Partners initiated coverage with an Outperform rating.
Entera Bio Ltd. is a biotechnology company based in Israel, primarily focused on the development of orally delivered large molecule therapeutics for use in areas traditionally addressed by injections. The company utilizes its proprietary drug delivery platform to enhance the oral bioavailability of drugs. According to the company's Form S-3 filing on August 21, 2026, the FDA accepted Entera's plan in June 2026 to conduct a single, randomized, double-blind, placebo-controlled, Phase 3 trial in approximately 750 postmenopausal women with osteoporosis. This trial will evaluate the percent change from baseline in total hip bone mineral density (BMD) at Month 12 to support a potential New Drug Application (NDA) submission for EB613, an oral human parathyroid hormone. The filing also noted that in December 2025, the FDA released the Determination for Qualification of BMD qualifying total hip BMD as a surrogate efficacy endpoint for fracture. Additionally, an August 18, 2026, Form 8-K filing announced the appointment of Dr. Riccardo Paolo Camisasca as the company's Chief Medical Officer.
On September 24, 2026, the day before the rating action, Entera Bio's stock closed at $2.80. This latest close of $2.80 represents a price change of -7.59% over one week, compared to a baseline close of $3.03 on September 17, 2026. Over a one-month period, the stock experienced a price change of -18.13% from a baseline close of $3.42 on August 24, 2026. For its latest quarterly earnings reported on August 7, 2026, Entera Bio reported an actual EPS of -0.14, compared to an estimated EPS of -0.0816. The company reported actual revenue of $0.00, which met the estimated revenue of $0.00.
Separate from Guggenheim's individual rating, the broader consensus target price for Entera Bio was $9.18 as of September 15, 2026, which represents an implied change of +227.86% from the prior consensus target mean of $9.18 recorded on August 28, 2026. The consensus target revision percent was 0.00%. As of the September 1, 2026 recommendation period, the aggregate analyst recommendations consisted of 2 strong buy, 4 buy, 1 hold, 0 sell, and 0 strong sell ratings, totaling 7 recommendations. This represents 85.7% positive recommendations, 14.3% hold recommendations, and 0.0% negative recommendations, which remained unchanged from the August 1, 2026 recommendation period.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 25, 2026 | Guggenheim | Buy | initiated coverage | |
| September 22, 2026 | Cantor Fitzgerald | Overweight | initiated coverage | |
| September 18, 2026 | Leerink Partners | Outperform | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.